Barclays assumed coverage of Arvinas (ARVN) with an Overweight rating and $16 price target The shares trade at a discount to the company’s cash balance following the “disappointing” Phase 3 data for vepdegestrant in breast cancer, the analyst tells investors in a research note. The firm says Arvinas has “several shots on goals” for generating share upside from its early stage clinical programs in oncology and neurology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas initiated with an Overweight at Barclays
- Arvinas and Pfizer’s FDA Nod for Cancer Drug
- Arvinas, Pfizer announce FDA acceptance of vepdegestrant NDA
- Arvinas Holding’s Strategic Uncertainties and Partnership Challenges Justify Hold Rating
- Arvinas price target raised to $24 from $18 at H.C. Wainwright